Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer

详细信息    查看全文

• 作者：S. Kaufmann ; J. Bedke ; S. Gatidis ; J. Hennenlotter ; U. Kramer…
• 关键词：Prostate cancer ; PCA3 ; PI ; RADS ; MRI ; MR ; guided biopsy ; Targeted prostate biopsy
• 刊名：World Journal of Urology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：34
• 期：4
• 页码：509-515
• 全文大小：518 KB
• 参考文献：1.Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, Claussen CD, Stenzl A, Schlemmer HP, Schilling D (2012) MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 30(2):213–218. doi:10.​1007/​s00345-011-0675-2 CrossRef PubMed
  2.Jeong CW, Ku JH, Moon KC, Hong SK, Byun SS, Cho JY, Kim HH, Kim SH, Lee SE, Kwak C (2012) Can conventional magnetic resonance imaging, prostate needle biopsy, or their combination predict the laterality of clinically localized prostate cancer? Urology 79(6):1322–1327. doi:10.​1016/​j.​urology.​2012.​01.​080 CrossRef PubMed
  3.van Hove A, Savoie PH, Maurin C, Brunelle S, Gravis G, Salem N, Walz J (2014) Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol 32(4):847–858. doi:10.​1007/​s00345-014-1332-3 CrossRef PubMed
  4.Colleselli D, Schilling D, Lichy MP, Hennenlotter J, Vogel UH, Krueger SA, Kuehs U, Schlemmer HP, Stenzl A, Schwentner C (2010) Topographical sensitivity and specificity of endorectal coil magnetic resonance imaging for prostate cancer detection. Urol Int 84(4):388–394. doi:10.​1159/​000300572 CrossRef PubMed
  5.Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, Corvin S, Sievert KD, Claussen CD, Stenzl A, Schlemmer HP (2006) MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 50(4):738–748. doi:10.​1016/​j.​eururo.​2006.​03.​007 (discussion 748–739) CrossRef PubMed
  6.Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Futterer J, Bouwense S, van Oort I, Schroder F, Huisman H, Barentsz J (2012) Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 61(1):177–184. doi:10.​1016/​j.​eururo.​2011.​08.​042 CrossRef PubMed
  7.Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ, European Society of Urogenital R (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757. doi:10.​1007/​s00330-011-2377-y CrossRef PubMed PubMedCentral
  8.Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59(23):5975–5979PubMed
  9.Busetto GM, De Berardinis E, Sciarra A, Panebianco V, Giovannone R, Rosato S, D’Errigo P, Di Silverio F, Gentile V, Salciccia S (2013) Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models. Urology 82(6):1355–1360. doi:10.​1016/​j.​urology.​2013.​06.​078 CrossRef PubMed
  10.Leyten GH, Wierenga EA, Sedelaar JP, van Oort IM, Futterer JJ, Barentsz JO, Schalken JA, Mulders PF (2013) Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int J Mol Sci 14(6):11347–11355. doi:10.​3390/​ijms140611347 CrossRef PubMed PubMedCentral
  11.Porpiglia F, Russo F, Manfredi M, Mele F, Fiori C, Bollito E, Papotti M, Molineris I, Passera R, Regge D (2014) The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? J Urol 192(1):60–66. doi:10.​1016/​j.​juro.​2014.​01.​030 CrossRef PubMed
  12.Falco T, Shenouda G, Kaufmann C, Belanger I, Procaccini C, Charrois C, Evans M (2002) Ultrasound imaging for external-beam prostate treatment setup and dosimetric verification. Med Dosim 27(4):271–273. doi:10.​1016/​s0958-3947(02)00144-9 CrossRef PubMed
  13.Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59(4):477–494. doi:10.​1016/​j.​eururo.​2010.​12.​009 CrossRef PubMed
  14.D’Amico AV, Whittington R, Malkowicz S et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974. doi:10.​1001/​jama.​280.​11.​969 CrossRef PubMed
  15.Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54(5):1081–1088. doi:10.​1016/​j.​eururo.​2008.​06.​071 CrossRef PubMed
  16.Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F (2007) Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 52(5):1309–1322. doi:10.​1016/​j.​eururo.​2007.​08.​006 CrossRef PubMed
  17.Zaytoun OM, Stephenson AJ, Fareed K, El-Shafei A, Gao T, Levy D, Jones JS (2012) When serial prostate biopsy is recommended: most cancers detected are clinically insignificant. BJU Int 110(7):987–992. doi:10.​1111/​j.​1464-410X.​2012.​10958.​x CrossRef PubMed
  18.Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, Kruecker J, Locklin J, Baccala AA Jr, Rastinehad AR, Merino MJ, Shih JH, Wood BJ, Pinto PA, Choyke PL (2011) Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 258(2):488–495. doi:10.​1148/​radiol.​10100667 CrossRef PubMed PubMedCentral
  19.De Luca S, Passera R, Bollito E, Milillo A, Scarpa RM, Papotti M, Coda R, Randone DF (2013) Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score. Anticancer Res 33(10):4657–4662PubMed
  20.Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69(3):532–535. doi:10.​1016/​j.​urology.​2006.​12.​014 CrossRef PubMed
  21.de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A (2011) Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 185(6):2119–2125. doi:10.​1016/​j.​juro.​2011.​01.​075 CrossRef PubMed
  22.Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF (2013) PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 190(1):64–69. doi:10.​1016/​j.​juro.​2013.​02.​018 CrossRef PubMed
  23.van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, Remzi M, Marberger M (2012) The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int 109(3):360–366. doi:10.​1111/​j.​1464-410X.​2011.​10377.​x CrossRef PubMed
  24.Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino PT, Schroder F, Lilja H (2010) Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 28(15):2493–2498. doi:10.​1200/​jco.​2009.​24.​1968 CrossRef PubMed PubMedCentral
  25.Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, Witjes JA (2011) Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 59(6):962–977. doi:10.​1016/​j.​eururo.​2011.​02.​034 CrossRef PubMed
  26.Kuru TH, Roethke MC, Rieker P, Roth W, Fenchel M, Hohenfellner M, Schlemmer HP, Hadaschik BA (2013) Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int 112(8):1080–1087. doi:10.​1111/​bju.​12259 CrossRef PubMed
  27.Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, Malavaud B (2012) Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 62(6):986–996. doi:10.​1016/​j.​eururo.​2012.​06.​044 CrossRef PubMed
  28.Rosenkrantz AB, Lim RP, Haghighi M, Somberg MB, Babb JS, Taneja SS (2013) Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI. AJR Am J Roentgenol 201(4):W612–W618. doi:10.​2214/​ajr.​12.​10173 CrossRef PubMed
  29.Schimmoller L, Quentin M, Arsov C, Lanzman RS, Hiester A, Rabenalt R, Antoch G, Albers P, Blondin D (2013) Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol 23(11):3185–3190. doi:10.​1007/​s00330-013-2922-y CrossRef PubMed
  30.Schimmoller L, Quentin M, Arsov C, Hiester A, Kropil P, Rabenalt R, Albers P, Antoch G, Blondin D (2014) Predictive power of the ESUR scoring system for prostate cancer diagnosis verified with targeted MR-guided in-bore biopsy. Eur J Radiol 83(12):2103–2108. doi:10.​1016/​j.​ejrad.​2014.​08.​006 CrossRef PubMed
  
• 作者单位：S. Kaufmann (1) (2)
  J. Bedke (2)
  S. Gatidis (1)
  J. Hennenlotter (2)
  U. Kramer (1)
  M. Notohamiprodjo (1)
  K. Nikolaou (1)
  A. Stenzl (2)
  S. Kruck (2)
  
  1. Department of Diagnostic and Interventional Radiology, Eberhard Karls University Tuebingen, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany
  2. Department of Urology, Eberhard Karls University Tuebingen, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Urology and Andrology
  Nephrology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-8726

文摘

Purpose Multiparametric magnetic resonance imaging (mpMRI) improves diagnostic accuracy in re-biopsies of men with prostate cancer (PC) suspicion, but predictive value is limited despite the use of the new Prostate Imaging Reporting and Data System (PI-RADS). Prognostic value of the PC-specific biomarker prostate cancer gene 3 (PCA3) added to the PI-RADS score was evaluated.